KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Current Taxes (2016 - 2020)

Supernus Pharmaceuticals (SUPN) has disclosed Current Taxes for 5 consecutive years, with $25.1 million as the latest value for Q2 2020.

  • Quarterly Current Taxes rose 836.87% to $25.1 million in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $25.1 million through Jun 2020, up 836.87% year-over-year, with the annual reading at $2.4 million for FY2019, 80.26% down from the prior year.
  • Current Taxes for Q2 2020 was $25.1 million at Supernus Pharmaceuticals, up from $9.1 million in the prior quarter.
  • The five-year high for Current Taxes was $25.1 million in Q2 2020, with the low at $7000.0 in Q4 2016.
  • Average Current Taxes over 5 years is $8.9 million, with a median of $7.5 million recorded in 2017.
  • The sharpest move saw Current Taxes skyrocketed 227585.71% in 2017, then crashed 80.26% in 2019.
  • Over 5 years, Current Taxes stood at $7000.0 in 2016, then surged by 227585.71% to $15.9 million in 2017, then decreased by 22.34% to $12.4 million in 2018, then plummeted by 80.26% to $2.4 million in 2019, then skyrocketed by 925.46% to $25.1 million in 2020.
  • According to Business Quant data, Current Taxes over the past three periods came in at $25.1 million, $9.1 million, and $2.4 million for Q2 2020, Q1 2020, and Q4 2019 respectively.